Some Effects of Low Molecular Weight Dextran on Coagulation^[*]

Summary

LMDX has been shown to affect adversely the rate of prothrombin consumption during coagulation and the structure of the fibrin clot when present in the concentrations usually recommended for clinical use. Its use in animals with hemostatic defects induced by the pump-oxygenator was accompanied by excessive bleeding. At the same time, however, it conferred some form of protection which led to improved survival. A manner of using LMDX so as to benefit from its protective action without endangering hemostasis is currently under study.

^* This work was supported in part by USPHS Grant NB-05651.

• References

• 1 Adelson E. Bleeding time prolongation, after dextran infusion. Bibi, haemat. (Basel) 07: 275 1958;
• 2 Bergentz S. E, Eiken O, Nilsson I. M. The effect of dextran of varions molecular weights on the coagulation in dogs. Thrombos. Diathes. haemorrh. (Stuttg) 06: 151 1961;
• 3 Breckenridge I. M, Walker W. F. Blood loss in open-heart surgery with low-molecular - weight dextran. Lancet I: 1190 1963;
• 4 Carbone J. V, Furth F. W, Scott Jr. R, Crosby W. H. An hemostatic defect associated with dextran infusions. Proc. Soc. exp. Biol. (N. Y) 85: 101 1954;
• 5 de Nicola P. Thrombelastography. Charles C. Thomas; Springfield, Ill: 1957
• 6 Fletcher A. P, Alkjaersig N, Sherry S. The maintenance of a sustained thrombolytic state in man. I Induction and effects. J. clin. Invest 38: 1096 1959;
• 7 Gaintner J. R, Jackson D. P, Conley C. L. Morphologic studies of clot retraction. Bull. Johns Hopkins Hosp 03: 266 1962;
• 8 Godal H. C. The interaction of protamine with human fibrinogen and the significance of this interaction for the coagulation of fibrinogen. Scand. J. clin Lab. Invest 12: 433 1960;
• 9 Graham J. B, Langdell R. D, Brinkhous K. M. Estimation of the rate of prothrombin utilization. In: The Coagulation of Blood: Methods of Study. ed. Tocantins L. M. 117 Grune and Stratton, N. Y.: 1955
• 10 Jacobaeus U. The effect of dextran on the coagulation of blood. Acta med. scand 151: 505 1955;
• 11 Jacobaeus U. Studies on the effect of dextran on the coagulation of blood. Acta med. scand., Suppl.. 322. 1957
• 12 Langdell R. D, Adelson E, Furth F. W, Crosby W. H. Dextran and prolonged bleeding time. J. Amer. med. Ass 166: 346 1958;
• 13 Long Jr. D. M, Sanchez L, Varco R. L, Lillehei C. W. The use of low molecular weight dextran and serum albumin as plasma expanders in extracorporeal circulation. Surgery 50: 12-47 1961;
• 14 Long Jr. D. M. The status of plasma expanders in open heart surgery. Dis. Chest 41: 578 1962;
• 15 Nilsson I. M, Eiken O. Further studies on the effect of dextran of various molecular weight on the coagulation mechanism. Thrombos. Diathes. haemorrh. (Stuttg) 11: 38 1964;
• 16 Ricketts C. R. Interaction of dextran and fibrinogen. Nature (Lond) 169: 970 1952;
• 17 Rodman Jr. M. F, Barrow E. M, Graham J. B. Diagnosis and control of the hemophilioid states with the partial thromboplastin time (PTT) test. Amer. J. clin. Path 29: 525 1958;
• 18 Ross S. W, Ebert R. V. Microelectrophoresis of blood platelets and the effects of dextran. J. clin. Invest 38: 155 1959;
• 19 Sawyer R. B, Moncrief J. A, Ganizaro P. G. Dextran therapy in thrombophlebitis. J. Amer, med. Ass 191: 136 1965;
• 20 Scott J. S. Blood coagulation failure in obstetrics. Brit. med. J II: 290 1955;
• 21 Sherry S, Lindemeyer R. I, Fletcher A. P, Alkjaersig N. Studies on enhanced fibrinolytic activity in man. J. clin. Invest 38: 810 1959;
• 22 Wells Jr. R. E. Kheology of blood in the micro vasculature. New Engl. J. Med 270: 832-889 1964;
• 23 Winfrey III E. W., Foster J. H. Antithrombogenic effect of low molecular weight dextran in small artery surgery. Arch. Surg 88: 78 1964;